Arch Therapeutics Inc (NASDAQ:ARTH) received a $3.00 price target from equities researchers at HC Wainwright in a research note issued on Thursday, July 27th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 334.78% from the stock’s current price.
A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. ValuEngine lowered shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, June 21st. Finally, Roth Capital set a $3.00 price target on shares of Arch Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $2.31.
Shares of Arch Therapeutics (ARTH) opened at 0.69 on Thursday. Arch Therapeutics has a 52-week low of $0.41 and a 52-week high of $0.80. The firm’s market cap is $101.44 million. The company’s 50 day moving average is $0.65 and its 200 day moving average is $0.59.
ILLEGAL ACTIVITY WARNING: “Arch Therapeutics Inc (NASDAQ:ARTH) PT Set at $3.00 by HC Wainwright” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/17/arch-therapeutics-inc-nasdaqarth-given-a-3-00-price-target-by-hc-wainwright-analysts-updated-updated.html.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
